Since no antibodies targeting mini-YARS or EMAP II-like domains were commercially applicable, the production, release, functional details, as well as the respective proportions of YARS-derived IL-8 and EMAP II mimics in GC remained unexplored in this study. This evidence concerns the gene AIMP1 and gastric cancer.